Emris Pharma
Preventing EGFRi skin toxicities, enhancing patient quality of life & Compliance for Cancer Patients
Company Overview
Snapshot
Founded in May 2023 by Lyora Aharonov, Emris Pharma operates with 1–10 employees. The company has secured funding across one round from two investors, including NGT HealthCare II. In June 2023, Emris Pharma launched the development of a new topical drug for treating skin toxicities.
Business overview
Emris Pharma is a Health Tech & Life Sciences company focused on developing innovative therapies to improve the quality of life for cancer patients. The company's core technology involves a novel small molecule, topically administered, designed to prevent skin toxicities induced by EGFR inhibitors (EGFRi). Emris Pharma's solution, SDT 011 (EMR-001), targets a significant global unmet need in the pharmaceutical and healthcare sectors, aiming to block the initial trigger of skin toxicity and enhance compliance with cancer treatment.
Strategic signal
In June 2023, Emris Pharma, a spin-off of Hadasit and Yissum, announced the launch of its innovative topical drug development for skin toxicities. This signals a strategic move to address a critical side effect of cancer treatment, potentially improving patient compliance and quality of life, and validating the company's approach in the pharmaceutical market.
Log in to access full profile ›Company Intelligence Q&A
- When was Emris Pharma founded?
- Emris Pharma was founded in May 2023.
- Who are the founders of Emris Pharma?
- Lyora Aharonov is a co-founder and CEO of Emris Pharma.
- What is Emris Pharma's primary focus?
- Emris Pharma focuses on developing a novel small molecule, topically administered drug to prevent skin toxicities induced by EGFR inhibitors, aiming to improve cancer patients' quality of life and compliance with therapy.
- Which investors participated in Emris Pharma's Pre-Seed funding round?
- In May 2023, Emris Pharma received Pre-Seed funding from NGT HealthCare II and the Israel Innovation Authority.
- What is the significance of Emris Pharma's launch?
- Emris Pharma launched in June 2023 as a spin-off of Hadasit and Yissum, initiating the development of a new topical drug designed to treat skin toxicities and improve the quality of life for cancer patients.